Thursday, Dec 10, 1992
South San Francisco, Calif. -- December 10, 1992 --December 10, 1992 -- Genentech, Inc. (NYSE: GNE) today announced the appointment of Kurt Kopp to the position of Genentech vice president and general manager of its new European organization. Kopp begins in this position on January 1, 1993."Kopp's appointment marks two major milestones for Genentech," said G. Kirk Raab, Genentech's president and chief executive officer, "the formation of our wholly owned European organization, and the initiation of an important commercial agreement with F. Hoffmann-La Roche Ltd. to commercialize Pulmozyme (rhDNase) in Europe." Kopp will report to Dick Brewer, vice president of Sales and Marketing.
Genentech announced last week that it had completed Pulmozyme's Phase III clinical trial for treating cystic fibrosis and would proceed to regulatory filings for that indication in the United States, Canada and Europe. The trial showed that the product improves lung function and reduces the rate of respiratory infection in cystic fibrosis patients. No major adverse side-effects were noted. Genentech plans to file for marketing approval for this indication in the United States and Canada in the first quarter of 1993. Similar filings with relevant regulatory agencies in Europe are expected shortly thereafter. Genentech is also investigating Pulmozyme for treating chronic bronchitis, currently in Phase II clinical trials in the United States and Europe.
As general manager of Genentech's European organization, Kopp will be responsible for developing plans and activities for the clinical development and marketing of Genentech products in Europe beginning with Pulmozyme. He also will be responsible for hiring and managing the European headquarters staff and sales force. Genentech's European headquarters will be located in or near Basel, Switzerland.Kopp joins Genentech from Roche, where his most recent position was in Basel as regional director for Latin America. Previously, he served as pharmaceutical division manager for Roche Spain, where he was responsible for sales, marketing, regulatory and medical affairs. While Kopp served in this position, Roche Spain launched seven new products, including the biotechnology products Neupogen® and Roferon-A®. Kopp began his career at Roche in 1980 in the international marketing group. He holds a master's degree in economics and business administration from the University of Basel."Kopp's background is well-suited to the challenges ahead for Genentech in Europe," said Brewer. "His strong international marketing experience will help with the successful establishment of our European organization and penetration of our products in these markets."Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant medical needs. The company has headquarters in South San Francisco, California and is traded on the New York and Pacific Stock exchanges under the symbol GNE. Roche Holding Ltd, Basel, Switzerland, holds an almost 62 percent equity position in Genentech.
# # #